NEW YORK, Sept. 2, 2015 /PRNewswire/ -- Levi & Korsinsky is commencing an investigation on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA). The investigation concerns whether Akebia and certain of its officers and/or directors have violated federal securities laws.
On March 20, 2014, Akebia held an initial public offering of its stock, offering 5.88 million shares at $17 per share. Then on October 27, 2014, Akebia announced the results of its Phase 2b Study of oral therapy AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease, citing a "higher incidence of serious adverse events (SAEs) reported in the active treatment group versus the placebo group" and "one was considered probably related to active treatment and two were considered possibly related, including one death." Upon this news, shares of Akebia stock fell from $19.72 per share on October 24, 2014, to $13.97 per share on October 27, 2014. To obtain additional information about this investigation, go to: http://zlk.9nl.com/akebia-therapeutics-akba or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
SOURCE Levi & Korsinsky, LLP